Summary & Overview
HCPCS J7322: Hymovis (hyaluronan) for Intra-articular Injection, 1 mg
HCPCS Level II code J7322 identifies a hyaluronan derivative product — Hymovis or Hymovis One — supplied in 1 mg units for intra-articular injection. The code is used to bill single milligram doses of viscosupplementation agents administered directly into a joint space, most commonly for symptomatic management of joint conditions.
This billing code matters nationally because hyaluronan injections are a widely used non-surgical option for joint symptom management and have implications for outpatient pharmaceutical spend, coverage policy, and utilization management across major payers. Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of what the code represents, the clinical and service contexts for its use, and the typical sites of service. Where available, the publication provides benchmarks, payer coverage considerations, and recent policy developments affecting injectable viscosupplements. Data not available in the input will be noted as such; the content avoids state-specific guidance and focuses on national relevance.
Billing Code Overview
HCPCS Level II code J7322 describes hyaluronan or derivative, hymovis or hymovis one, for intra-articular injection, 1 mg. This code represents a single milligram unit of a hyaluronan derivative intended for intra-articular administration to address joint conditions, typically delivered directly into the synovial space.
Service Type: Intra-articular viscosupplementation injection
Typical Site of Service: Outpatient clinic or physician office, ambulatory surgical center, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient is a 55-year-old physically active individual with symptomatic osteoarthritis of the knee presenting to an orthopedic or sports medicine clinic after conservative measures (oral NSAIDs, physical therapy, activity modification) provide insufficient relief. The clinician confirms persistent joint-line pain, stiffness, and functional limitation on exam and obtains plain radiographs showing mild-to-moderate joint space narrowing. After shared decision-making, the provider schedules an intra-articular viscosupplementation injection using J7322 (hyaluronan derivative, Hymovis or Hymovis One, 1 mg) to improve joint lubrication and reduce pain.
The clinical workflow includes: referral or office visit evaluation; informed consent and discussion of risks/benefits; preparation of sterile field; aspiration of effusion if present; localization of the joint (palpation or ultrasound guidance as indicated); intra-articular injection of the appropriate volume of the product billed with J7322; post-injection observation for immediate adverse effects; documentation of drug name, dose, lot number, injection site, and patient response. Typical site of service is an outpatient clinic, physician office, or ambulatory surgical center when multiple joints or additional procedures are performed. The procedure is commonly performed by orthopedic surgeons, sports medicine physicians, rheumatologists, or physiatry specialists.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|